ONCOZ Stock Overview
A pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OncoZenge AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.50 |
| 52 Week High | SEK 12.10 |
| 52 Week Low | SEK 2.40 |
| Beta | 1.16 |
| 11 Month Change | -66.13% |
| 3 Month Change | -44.35% |
| 1 Year Change | -0.14% |
| 33 Year Change | -66.39% |
| 5 Year Change | n/a |
| Change since IPO | -77.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONCOZ | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -59.1% | 0.9% | -0.2% |
| 1Y | -0.1% | 9.3% | 11.8% |
Return vs Industry: ONCOZ underperformed the Swedish Pharmaceuticals industry which returned 9.3% over the past year.
Return vs Market: ONCOZ underperformed the Swedish Market which returned 11.8% over the past year.
Price Volatility
| ONCOZ volatility | |
|---|---|
| ONCOZ Average Weekly Movement | 21.3% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ONCOZ's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ONCOZ's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 2 | Stian Kildal | oncozenge.com |
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.
OncoZenge AB (publ) Fundamentals Summary
| ONCOZ fundamental statistics | |
|---|---|
| Market cap | SEK 40.94m |
| Earnings (TTM) | -SEK 9.36m |
| Revenue (TTM) | SEK 3.00k |
Over9,999x
P/S Ratio-4.4x
P/E RatioIs ONCOZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCOZ income statement (TTM) | |
|---|---|
| Revenue | SEK 3.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 3.00k |
| Other Expenses | SEK 9.36m |
| Earnings | -SEK 9.36m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.80 |
| Gross Margin | 100.00% |
| Net Profit Margin | -311,900.00% |
| Debt/Equity Ratio | 0% |
How did ONCOZ perform over the long term?
See historical performance and comparison